Extended Wear Advantage CeQur Simplicity recently gained FDA clearance for extended wear up to seven days, with a 4-day patch already in use and a 1-unit device introduced. This presents a compelling cross-sell and upsell opportunity to patients seeking fewer daily injections and to clinics aiming to simplify insulin regimens.

Clinician and Patient Demand The combination of real-world data presentations at major diabetes conferences and ongoing regulatory clearances signals strong market validation. Use this momentum to approach endocrinologists and payers about adopting Simplidity as a preferred mealtime insulin delivery option to improve adherence and reduce injection burden.

Strategic Financing Recent substantial equity rounds, including a $100M Series E, indicate strong investor confidence and available capital for expansion. This can support co-marketing, regional partnerships, and sales teams targeting hospitals, clinics, and diabetes centers with unmet needs for convenient insulin delivery.

Product Line Expansion Introductions of new formats such as extended wear patches and a 1-unit device diversify the product portfolio. This creates opportunities to target a broader patient base from new-to-therapy to those requiring smaller dose units, as well as payers seeking cost-effective, patient-friendly devices.

Regional and Brand Synergy Headquartered in Switzerland with a global tech stack and digital presence, CeQur can leverage international healthcare networks, multilingual markets, and digital marketing channels to accelerate adoption across Europe and other regions, aligning with existing diabetes device ecosystems.